Varicella and varicella vaccination in South Korea

Sung Hee Oh, Eun Hwa Choi, Seon Hee Shin, Yun Kyung Kim, Jin Keun Chang, Kyong Min Choi, Jae Kyun Hur, Kyung Hyo Kim, Jae Youn Kim, Eun Hee Chung, Soo Young Lee, Su Eun Park, Sungho Cha, Kwang Nam Kim, Sang Hyuk Ma, Byung Wook Eun, Nam Hee Kim, Dae Sun Jo, Bo Youl Choi, Shin Ah Kim

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

With continuing occurrence of varicella despite increasing vaccine coverage for the past 20 years, a case-based study, a case-control study, and an immunogenicity and safety study were conducted to address the impact of varicella vaccination in South Korea. Varicella patients under the age of 16 years were enrolled for the case-based study. For the case-control study, varicella patients between 12 months and 15 years of age were enrolled with one control matched for each patient. For the immunogenicity and safety study, otherwise healthy children from 12 to 24 months old were immunized with Suduvax (Green Cross, South Korea). Fluorescent antibody to membrane antigen (FAMA) varicella-zoster virus (VZV) antibody was measured before and 6 weeks after immunization. In the case-based study, the median age of the patients was 4 years. Among 152 patients between 1 and 15 years of age, 139 children received varicella vaccine and all had breakthrough infections. Clinical courses were not ameliorated in vaccinated patients, but more vaccinated patients received outpatient rather than inpatient care. In the case-control study, the adjusted overall effectiveness of varicella vaccination was 54%. In the immunogenicity and safety study, the seroconversion rate and geometric mean titer for FAMA antibody were 76.67% and 5.31. Even with increasing varicella vaccine uptake, we illustrate no upward age shift in the peak incidence, a high proportion of breakthrough disease, almost no amelioration in disease presentation by vaccination, and insufficient immunogenicity of domestic varicella vaccine. There is need to improve the varicella vaccine used in South Korea.

Original languageEnglish
Pages (from-to)762-768
Number of pages7
JournalClinical and Vaccine Immunology
Volume21
Issue number5
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Chickenpox Vaccine
Republic of Korea
Chickenpox
Vaccination
Antibodies
Case-Control Studies
Immunization
Membranes
Antigens
Safety
Viruses
Vaccines
Human Herpesvirus 3
Inpatients
Outpatients
Incidence
Infection

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Clinical Biochemistry
  • Microbiology (medical)

Cite this

Oh, S. H., Choi, E. H., Shin, S. H., Kim, Y. K., Chang, J. K., Choi, K. M., ... Kim, S. A. (2014). Varicella and varicella vaccination in South Korea. Clinical and Vaccine Immunology, 21(5), 762-768. https://doi.org/10.1128/CVI.00645-13

Varicella and varicella vaccination in South Korea. / Oh, Sung Hee; Choi, Eun Hwa; Shin, Seon Hee; Kim, Yun Kyung; Chang, Jin Keun; Choi, Kyong Min; Hur, Jae Kyun; Kim, Kyung Hyo; Kim, Jae Youn; Chung, Eun Hee; Lee, Soo Young; Park, Su Eun; Cha, Sungho; Kim, Kwang Nam; Ma, Sang Hyuk; Eun, Byung Wook; Kim, Nam Hee; Jo, Dae Sun; Choi, Bo Youl; Kim, Shin Ah.

In: Clinical and Vaccine Immunology, Vol. 21, No. 5, 01.01.2014, p. 762-768.

Research output: Contribution to journalArticle

Oh, SH, Choi, EH, Shin, SH, Kim, YK, Chang, JK, Choi, KM, Hur, JK, Kim, KH, Kim, JY, Chung, EH, Lee, SY, Park, SE, Cha, S, Kim, KN, Ma, SH, Eun, BW, Kim, NH, Jo, DS, Choi, BY & Kim, SA 2014, 'Varicella and varicella vaccination in South Korea', Clinical and Vaccine Immunology, vol. 21, no. 5, pp. 762-768. https://doi.org/10.1128/CVI.00645-13
Oh, Sung Hee ; Choi, Eun Hwa ; Shin, Seon Hee ; Kim, Yun Kyung ; Chang, Jin Keun ; Choi, Kyong Min ; Hur, Jae Kyun ; Kim, Kyung Hyo ; Kim, Jae Youn ; Chung, Eun Hee ; Lee, Soo Young ; Park, Su Eun ; Cha, Sungho ; Kim, Kwang Nam ; Ma, Sang Hyuk ; Eun, Byung Wook ; Kim, Nam Hee ; Jo, Dae Sun ; Choi, Bo Youl ; Kim, Shin Ah. / Varicella and varicella vaccination in South Korea. In: Clinical and Vaccine Immunology. 2014 ; Vol. 21, No. 5. pp. 762-768.
@article{ed048aeb1eb14efeb1bcaba4c36b40a6,
title = "Varicella and varicella vaccination in South Korea",
abstract = "With continuing occurrence of varicella despite increasing vaccine coverage for the past 20 years, a case-based study, a case-control study, and an immunogenicity and safety study were conducted to address the impact of varicella vaccination in South Korea. Varicella patients under the age of 16 years were enrolled for the case-based study. For the case-control study, varicella patients between 12 months and 15 years of age were enrolled with one control matched for each patient. For the immunogenicity and safety study, otherwise healthy children from 12 to 24 months old were immunized with Suduvax (Green Cross, South Korea). Fluorescent antibody to membrane antigen (FAMA) varicella-zoster virus (VZV) antibody was measured before and 6 weeks after immunization. In the case-based study, the median age of the patients was 4 years. Among 152 patients between 1 and 15 years of age, 139 children received varicella vaccine and all had breakthrough infections. Clinical courses were not ameliorated in vaccinated patients, but more vaccinated patients received outpatient rather than inpatient care. In the case-control study, the adjusted overall effectiveness of varicella vaccination was 54{\%}. In the immunogenicity and safety study, the seroconversion rate and geometric mean titer for FAMA antibody were 76.67{\%} and 5.31. Even with increasing varicella vaccine uptake, we illustrate no upward age shift in the peak incidence, a high proportion of breakthrough disease, almost no amelioration in disease presentation by vaccination, and insufficient immunogenicity of domestic varicella vaccine. There is need to improve the varicella vaccine used in South Korea.",
author = "Oh, {Sung Hee} and Choi, {Eun Hwa} and Shin, {Seon Hee} and Kim, {Yun Kyung} and Chang, {Jin Keun} and Choi, {Kyong Min} and Hur, {Jae Kyun} and Kim, {Kyung Hyo} and Kim, {Jae Youn} and Chung, {Eun Hee} and Lee, {Soo Young} and Park, {Su Eun} and Sungho Cha and Kim, {Kwang Nam} and Ma, {Sang Hyuk} and Eun, {Byung Wook} and Kim, {Nam Hee} and Jo, {Dae Sun} and Choi, {Bo Youl} and Kim, {Shin Ah}",
year = "2014",
month = "1",
day = "1",
doi = "10.1128/CVI.00645-13",
language = "English",
volume = "21",
pages = "762--768",
journal = "Clinical and Vaccine Immunology",
issn = "1556-6811",
publisher = "American Society for Microbiology",
number = "5",

}

TY - JOUR

T1 - Varicella and varicella vaccination in South Korea

AU - Oh, Sung Hee

AU - Choi, Eun Hwa

AU - Shin, Seon Hee

AU - Kim, Yun Kyung

AU - Chang, Jin Keun

AU - Choi, Kyong Min

AU - Hur, Jae Kyun

AU - Kim, Kyung Hyo

AU - Kim, Jae Youn

AU - Chung, Eun Hee

AU - Lee, Soo Young

AU - Park, Su Eun

AU - Cha, Sungho

AU - Kim, Kwang Nam

AU - Ma, Sang Hyuk

AU - Eun, Byung Wook

AU - Kim, Nam Hee

AU - Jo, Dae Sun

AU - Choi, Bo Youl

AU - Kim, Shin Ah

PY - 2014/1/1

Y1 - 2014/1/1

N2 - With continuing occurrence of varicella despite increasing vaccine coverage for the past 20 years, a case-based study, a case-control study, and an immunogenicity and safety study were conducted to address the impact of varicella vaccination in South Korea. Varicella patients under the age of 16 years were enrolled for the case-based study. For the case-control study, varicella patients between 12 months and 15 years of age were enrolled with one control matched for each patient. For the immunogenicity and safety study, otherwise healthy children from 12 to 24 months old were immunized with Suduvax (Green Cross, South Korea). Fluorescent antibody to membrane antigen (FAMA) varicella-zoster virus (VZV) antibody was measured before and 6 weeks after immunization. In the case-based study, the median age of the patients was 4 years. Among 152 patients between 1 and 15 years of age, 139 children received varicella vaccine and all had breakthrough infections. Clinical courses were not ameliorated in vaccinated patients, but more vaccinated patients received outpatient rather than inpatient care. In the case-control study, the adjusted overall effectiveness of varicella vaccination was 54%. In the immunogenicity and safety study, the seroconversion rate and geometric mean titer for FAMA antibody were 76.67% and 5.31. Even with increasing varicella vaccine uptake, we illustrate no upward age shift in the peak incidence, a high proportion of breakthrough disease, almost no amelioration in disease presentation by vaccination, and insufficient immunogenicity of domestic varicella vaccine. There is need to improve the varicella vaccine used in South Korea.

AB - With continuing occurrence of varicella despite increasing vaccine coverage for the past 20 years, a case-based study, a case-control study, and an immunogenicity and safety study were conducted to address the impact of varicella vaccination in South Korea. Varicella patients under the age of 16 years were enrolled for the case-based study. For the case-control study, varicella patients between 12 months and 15 years of age were enrolled with one control matched for each patient. For the immunogenicity and safety study, otherwise healthy children from 12 to 24 months old were immunized with Suduvax (Green Cross, South Korea). Fluorescent antibody to membrane antigen (FAMA) varicella-zoster virus (VZV) antibody was measured before and 6 weeks after immunization. In the case-based study, the median age of the patients was 4 years. Among 152 patients between 1 and 15 years of age, 139 children received varicella vaccine and all had breakthrough infections. Clinical courses were not ameliorated in vaccinated patients, but more vaccinated patients received outpatient rather than inpatient care. In the case-control study, the adjusted overall effectiveness of varicella vaccination was 54%. In the immunogenicity and safety study, the seroconversion rate and geometric mean titer for FAMA antibody were 76.67% and 5.31. Even with increasing varicella vaccine uptake, we illustrate no upward age shift in the peak incidence, a high proportion of breakthrough disease, almost no amelioration in disease presentation by vaccination, and insufficient immunogenicity of domestic varicella vaccine. There is need to improve the varicella vaccine used in South Korea.

UR - http://www.scopus.com/inward/record.url?scp=84899748388&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899748388&partnerID=8YFLogxK

U2 - 10.1128/CVI.00645-13

DO - 10.1128/CVI.00645-13

M3 - Article

C2 - 24671555

AN - SCOPUS:84899748388

VL - 21

SP - 762

EP - 768

JO - Clinical and Vaccine Immunology

JF - Clinical and Vaccine Immunology

SN - 1556-6811

IS - 5

ER -